Quantity of eligible clients: CDEC reviewed the uncertainty in the quantity of clients with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some clients that are classified as getting moderate or reasonable condition might have a severe bleeding phenotype, https://hemgenix51615.dgbloggers.com/36535128/the-definitive-guide-to-hemgenix